(A) Bar graph of LXA4 concentration in pg/ml measured in human serum by ELISA. Healthy subjects, n = 41; all uveitis patients, n = 78; and breakdown of uveitis diagnoses within all patient samples, n = 2 to 23 per diagnosis. C57BL/6J mice were immunized with 300 μg IRBP651-670 and tissues collected for analyses on days 10 and 16 post-immunization for panels B-I. (B) Lipidomic analysis of inguinal lymph nodes from naïve and EAU-challenged mice on day 16. Peaks are representative multiple reaction monitoring LC-MS/MS chromatograms for specific ion transitions: LXA4 (m/z 351 > 115), 5-HETE (m/z 319 > 115), 15-HETE (m/z 319 > 175). (C) LXA4 and its pathway markers in pg per mg of tissue in whole eye globes, submandibular lymph nodes, distal (axillary + brachial) lymph nodes, and inguinal lymph nodes quantified by LC-MS/MS from unimmunized naïve and EAU-challenged mice (days 10 and 16). n = 5 per group. (D–E) Temporal expression of Alox5, Alox15 and Fpr2 in (D) retinas, and (E) inguinal lymph nodes during EAU (days 3, 7, 14) in comparison to the respective tissue from naïve mice quantified by RT-PCR. n = 6 per group. (F) Fpr2 expression on CD4+ T cells isolated from inguinal lymph nodes of naive and immunized mice, n = 6 per group. *p<0.05, **p<0.01, One-way ANOVA and Mann-Whitney test.